ArticleScience (New York, N.Y.)2022
New subvariants are masters of immune evasion.
Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- γδ T cells: origin and fate, subsets, diseases and immunotherapy.Signal transduction and targeted therapy · 2023Review
- Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.Nature communications · 2023Article
- Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches.Molecular immunology · 2023Review
- Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation.Frontiers in immunology · 2023Article
- A critical analysis of the current state of virus taxonomy.Frontiers in microbiology · 2023Review
- Selective sweeps in SARS-CoV-2 variant competition.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.Signal transduction and targeted therapy · 2022Review
- Renaming the SARS-CoV-2 Omicron sublineages as SARS-CoV-3 is contrary to nomenclature standards based on evolutionary and serological evidence.Clinical and translational medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines and prior infection still prevent severe disease from new SARS-CoV-2 strains.
Indexed as
Identifiers
35549399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.